156
Participants
Start Date
March 27, 2008
Primary Completion Date
May 5, 2010
Study Completion Date
September 23, 2011
AMG 479
AMG 479 administered with exemestane or fulvestrant
Placebo
Placebo administered with either exemestane or fulvestrant
Research Site, Dublin
Research Site, Dublin
Research Site, Waratah
Research Site, Footscray
Research Site, Malvern
Research Site, Geelong
Research Site, Woodville South
Research Site, Lucerne
Research Site, Chur
Research Site, Zurich
Research Site, Pittsburgh
Research Site, Hershey
Research Site, Dijon
Research Site, High Point
Research Site, Madrid
Research Site, Marietta
Research Site, Hanover
Research Site, Atlanta
Research Site, Gainesville
Research Site, Coral Springs
Research Site, Boca Raton
Research Site, Boynton Beach
Research Site, Lake Worth
Research Site, Montpellier
Research Site, Memphis
Research Site, Saint-Herblain
Research Site, Reims
Research Site, Frankfurt
Research Site, Chicago
Research Site, Frankfurt
Research Site, Lyon
Research Site, Le Mans
Research Site, Paris
Research Site, Munich
Research Site, American Fork
Research Site, Chandler
Research Site, Beverly Hills
Research Site, Montebello
Research Site, Duarte
Research Site, Sylmar
Research Site, Anaheim
Research Site, San Francisco
Research Site, Concord
Research Site, Tacoma
Research Site, Stamford
Research Site, Lebanon
Research Site, Denville
Research Site, Vancouver
Research Site, Ottawa
Research Site, Sault Ste. Marie
Research Site, Toronto
Research Site, Montreal
Research Site, Nice
Research Site, Barcelona
Research Site, L'Hospitalet de Llobregat
Research Site, Sabadell
Research Site, Derby
Research Site, London
Research Site, Manchester
Research Site, Peterborough
Lead Sponsor
NantCell, Inc.
INDUSTRY